Autres langues Gilead Sciences, Inc.

Actions

GILD

US3755581036

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 21/07/2026 Pré-ouverture 01:52:16
130,28 USD -2,20% Graphique intraday de Gilead Sciences, Inc. 132,28 +1,54%

Autres langues

21/07 Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
21/07 Gilead Sciences Shares Fall After Downgrade From Leerink Partners
21/07 Gilead, Merck weekly HIV pill keeps virus suppressed in late-stage trials
21/07 Analystenempfehlungen: VAT, Belimo, Richemont, Salesforce, Goldman Sachs, Crowdstrike…
21/07 Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure
21/07 Analyst recommendations: Gilead, Salesforce, Goldman Sachs, Carvana, Crowdstrike…
16/07 Kalshi to allow bets on clinical trials, FDA decisions
15/07 African markets - factors to watch on July 15
14/07 Congo begins trial of Gilead's experimental antiviral for Ebola Bundibugyo
08/07 Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says
08/07 Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says
06/07 Analyst recommendations: Chubb, Delta Air Lines, Pfizer, AMD, Dow…
03/07 Trial for Ebola treatment starts in DR Congo
02/07 Gilead Sciences : Supports the PARTNERS Trial to Advance Research on Potential Treatments for Ebola Virus Disease
02/07 Trial for Bundibugyo Ebola treatment starts in DRC, WHO says
30/06 Africa CDC seeks $18 million in urgent support for Ebola drug trials in DRC
29/06 Gilead Sciences, Inc.(NasdaqGS:GILD) dropped from Russell 1000 Growth-Defensive Index
29/06 Gilead Sciences, Inc.(NasdaqGS:GILD) dropped from Russell Top 200 Growth Benchmark
29/06 Gilead Sciences, Inc.(NasdaqGS:GILD) dropped from Russell 3000E Growth Benchmark
29/06 Gilead Sciences, Inc.(NasdaqGS:GILD) dropped from Russell 3000 Growth Benchmark
29/06 Gilead Sciences, Inc.(NasdaqGS:GILD) dropped from Russell 1000 Dynamic Index
29/06 Gilead Sciences, Inc.(NasdaqGS:GILD) dropped from Russell 1000 Growth Benchmark
25/06 Major deals involving US drugmakers and biotechs over the past decade
24/06 Gilead Says FDA Approves Trodelvy for First-Line Treatment of Advanced Triple-Negative Breast Cancer
24/06 Gilead Gets FDA Approval for Treatment for Aggressive Form of Breast Cancer
Aucun résultat pour cette recherche